Eric Venker Sells 100,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 100,000 shares of the company's stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total transaction of $1,132,000.00. Following the transaction, the chief operating officer now owns 606,525 shares of the company's stock, valued at approximately $6,865,863. This represents a 14.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Eric Venker also recently made the following trade(s):

• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00.

Roivant Sciences Stock Up 6.0 %

ROIV traded up $0.71 during trading on Friday, reaching $12.53. 11,220,827 shares of the stock traded hands, compared to its average volume of 5,857,028. The stock's 50-day moving average is $11.68 and its 200 day moving average is $11.32. Roivant Sciences Ltd. has a 12 month low of $8.61 and a 12 month high of $13.06. The stock has a market capitalization of $9.27 billion, a PE ratio of 2.10 and a beta of 1.24.

Institutional Investors Weigh In On Roivant Sciences

Several large investors have recently added to or reduced their stakes in the business. Gladius Capital Management LP bought a new stake in Roivant Sciences in the third quarter valued at $35,000. nVerses Capital LLC bought a new stake in Roivant Sciences in the 2nd quarter valued at about $34,000. US Bancorp DE raised its stake in Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company's stock worth $38,000 after buying an additional 1,948 shares during the period. Point72 Hong Kong Ltd bought a new position in Roivant Sciences in the second quarter worth approximately $36,000. Finally, Quarry LP acquired a new stake in Roivant Sciences in the second quarter valued at approximately $53,000. Institutional investors and hedge funds own 64.76% of the company's stock.

Analyst Ratings Changes

A number of brokerages have issued reports on ROIV. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Roivant Sciences in a report on Thursday, September 19th. Bank of America raised their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a "neutral" rating in a report on Wednesday, September 11th. Finally, HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Roivant Sciences currently has an average rating of "Moderate Buy" and an average target price of $17.93.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.